Addition of y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

HIGHLIGHTS

• who: Osman Öcal from the extrahepatic disease did not significantly lower treatment outcome [45]There were more patients with ALBI grade , liver function in the sorafenib arm. However, there was no difference in the overall survival between treatment arms. Despite these limitations, this study comprises a cohort collected prospectively within a multicenter trial and only the patients treated strictly following the study protocol, and it represents the largest cohort in the literature showing the additional effect of RE on tumor response in patients receiving sorafenib. In conclusion, our study showed that the addition of radioembolization resulted in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.